Evidence map›Paper›PMID 36235540›Full record

ArticleNutrients2022

Hyaluronan Oligosaccharides-Coated Paclitaxel-Casein Nanoparticles with Enhanced Stability and Antitumor Activity.

Man Wang, Yahui Zhang, Zuqi Fei, Dongchao Xie, Haihua Zhang, Qizhen Du, Peng Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Man WangDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.
Yahui ZhangDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.ORCID 0000-0003-3281-9830
Zuqi FeiDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.
Dongchao XieDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.
Haihua ZhangDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.
Qizhen DuDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.ORCID 0000-0003-2969-2840
Peng JinDepartment of Food Science and Technology, College of Food and Health, Zhejiang A & F University, Hangzhou 311300, China.ORCID 0000-0003-0032-8914

Funding

Key R&D Program Project of Zhejiang Province 2022C02033
6 · The paper itself

Abstract

This study aims to develop specific-molecular-weight hyaluronic acid oligosaccharides-coated paclitaxel-loaded casein nanoparticles (HA-PT-Cas NPs) via chemical conjugation to increase the stability and antitumor effects. Optimized HA-PT-Cas NPs (HA/casein of 3:1) were obtained with a mean size of 235.3 nm and entrapment efficiency of 93.1%. HA-PT-Cas exhibited satisfactory stability at 4 °C for 12 days and 37 °C for 3 h; paclitaxel was retained at rates of 81.4% and 64.7%, respectively, significantly higher than those of PT-Cas (only 27.8% at 4 °C after 16 h and 20.3% at 37 °C after 3 h). HA-PT-Cas exhibited high efficiency (61.3%) in inhibiting A375 tumor owing to the enhanced stability of HA oligosaccharides barrier, which was comparable with that of 10 μg/mL cis-platinum (64.9%). Mice experiments showed the 74.6% tumor inhibition of HA-PT-Cas by intravenously administration, significantly higher than that of PT-casein (39.8%). Therefore, this work provides an effective carrier for drug delivery via HA oligomers-coated modification.

Indexed as

NanoparticlesPaclitaxelAnimalsCaseinsCell Line, TumorCisplatinDrug CarriersDrug Delivery SystemsHyaluronic AcidMiceOligosaccharidesCaseinsCisplatinDrug CarriersHyaluronic AcidOligosaccharidesPaclitaxelbovine caseindrug deliveryencapsulationhyaluronic acid oligosaccharidepaclitaxel

Identifiers

PMID36235540
PMCPMC9573597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.